Showing results (171-180 of 186) with videos related to
Sort By:
Pageof 19
British Journal of Urology|December 1, 1980
Penile prostheses for the treatment of impotenceA S Narayana, S A Loening, C E Hawtrey, et al.The Journal of Urology|September 1, 1978
Biopsy and clinical course after cryosurgery for prostatic cancerD S Petersen, L A Milleman, E F Rose, et al.The Journal of Clinical Investigation|September 1, 1996
Induction of monocyte expression of tumor necrosis factor alpha by the 30-kD alpha antigen of Mycobacterium tuberculosis and synergism with fibronectinH Aung, Z Toossi, J J Wisnieski, et al.Journal of Immunology Research|October 28, 2017
Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector CellsShiming Ye, Melvin I Fox, Nicole A Belmar, et al.Frontiers in Immunology|January 11, 2014
Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakRJames W Purcell, Han K Kim, Sonia G Tanlimco, et al.Antimicrobial Agents and Chemotherapy|July 31, 2013
Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1D A Wilfret, J Walker, K K Adkison, et al.Urology|July 1, 1983
Cryosurgery in prostatic cancer: elimination of local lesionW W Bonney, B Fallon, W L Gerber, et al.Urology|January 1, 1982
Cryosurgery in prostatic cancer: survivalW W Bonney, B Fallon, W L Gerber, et al.Journal of Cancer Research and Clinical Oncology|October 18, 2012
Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAbDebra T Chao, Mian Su, Sonia Tanlimco, et al.Pageof 19